Watanabe S, et al. - Researchers investigated necitumumab plus gemcitabine and cisplatin (GC + N) in patients with previously untreated squamous non-small cell lung cancer in Japan in this open-label, multicenter, phase 1b/2 study. In the phase 1b part, determination of gemcitabine dose was done for the phase 2 part, in which randomization of patients 1:1 to GC + N or gemcitabine and cisplatin (GC) was done (gemcitabine 1250 mg/m² on days 1 and 8; cisplatin 75 mg/m² on day 1 of maximum four 3-week cycles; nectimumab 800 mg on days 1 and 8 of a 3-week cycle continued until progressive disease or unacceptable toxicity). Patients receiving GC + N, in the first-line treatment, well-tolerated it and displayed a significant and clinically meaningful treatment benefit.